Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. - Wikidata - wikimedia - TriplyDB

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

http://www.wikidata.org/entity/Q44399980

about

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Cord Blood as a Source of Natural Killer Cells Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies Childhood acute myeloid leukaemia Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.Natural killer cells in human cancer: from biological functions to clinical applications Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Harnessing adaptive natural killer cells in cancer immunotherapy Understanding of molecular mechanisms in natural killer cell therapy Cytotoxicity of activated natural killer cells against pediatric solid tumors.Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Isolation and characterization of canine natural killer cells.Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.Biology and clinical effects of natural killer cells in allogeneic transplantation.Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.The impact of HLA and KIR ligand mismatching on unrelated allogeneic hematopoietic stem cell transplantation in Korean adult patients Natural killer cell-based therapies.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Haematopoietic stem cell transplantation: indications, clinical developments and future directions.Treatment advances in multiple myeloma.Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods Protective genotypes in HIV infection reflect superior function of KIR3DS1+ over KIR3DL1+ CD8+ T cells.Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.New approaches for preventing and treating chronic graft-versus-host disease.The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

P2860

Q26765459-4D5FB57E-3A6F-4EF5-93B8-25192E6A3564 Q26771337-D188269A-53B0-4B01-8A21-3BACC48F39FD Q26777209-B8F54FA5-33E9-4A09-A591-BA623B6446C2 Q26996660-E79AA3C2-21CB-4E60-A8D0-67AF9B85273E Q27005960-FE87A887-AC3C-485C-B94F-A40DB83EA024 Q27301956-567D0839-D51D-4F7D-98E9-688BF838CA4D Q27691427-FE4F9988-DBB0-47B5-AAEF-30B9C2C47ADB Q28067102-08A4C0D5-2CF6-4A3C-A1D5-E8BC649AF810 Q28080914-8420D009-7FD7-4BDF-A74E-F6D0FD90F2D0 Q28081448-D083026B-55FE-42E4-8B40-E3D68E1FEFF3 Q28086976-C4B8223A-8D1C-4050-9396-5311AE61ADED Q30503995-9B6E5232-8970-4590-827D-F1C4F94CFEF4 Q33378868-1383B198-AE1A-415D-9BFD-EFFB0CAB5E21 Q33558780-1EEC7EF5-F2B2-4216-B0F1-3B92AFCB3FBB Q33605114-F204474F-1D08-4C4B-A698-85FEA1C7D130 Q33642419-9D852A9D-D5F2-415E-925A-A4A551E90A18 Q33651178-FDED26DF-1418-4A00-A664-08F3F4CD6E15 Q33672480-25447C2F-E203-4BCF-8D84-81DD42FFF6F6 Q33780272-B3607B34-60D8-4C0C-9507-7A2FB1CFE547 Q33787859-405A6233-4FFE-49A0-B339-E98016720D7E Q33893091-07107EE4-E43F-4958-8706-CE8A321A165E Q33893173-B19E4FE9-61D8-4A59-B9B5-DFA6DFD50CA2 Q34088081-181488AC-619D-4505-950B-17B9F01E5634 Q34193507-0AF41C68-9FAF-4417-933D-FCBAB77D30A6 Q34307792-AE23A2D8-B3C9-4177-BEAC-1BC188171F85 Q34551581-E4ECCC99-CD6F-4D8C-B6D2-903BF9721ECB Q34749582-A39E72C4-94FB-4ADA-BEBE-721FBA4C85FF Q34988727-F61D78E8-D77B-4AE6-84CA-AA460F198314 Q35029441-97BCB39C-E05E-4C38-8E3F-E20F58949AE5 Q35609690-7E0CA491-6714-4765-9249-229870950EB9 Q35688848-8B48C3AB-4EAC-41F0-A841-86A19267235C Q35751074-0CB0E82C-F2A8-438F-ACB8-2067E8E2485B Q35800831-B5192403-80CF-4B89-869B-E32A45DBD867 Q35828810-AA730CE7-D427-47F1-BEDB-5FAEF7C01517 Q35830835-4A3A478F-F547-443F-95E9-1DB89EB88C13 Q35846887-BE31B01B-3F77-498D-99F1-01DEF17E7FCD Q35847425-2BD63466-F3EC-440F-9EB5-E813031C0D65 Q35847596-286C3142-7E54-46E0-99F6-FB081BB4DD61 Q35847668-49771F8C-837A-471F-BA20-93E5896A5730 Q35847820-2972E7E9-C023-4213-8625-5FA924E31557

P2860

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

http://www.wikidata.org/entity/Q44399980

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Survival advantage with KIR li ...... ntation from unrelated donors.

@en

Survival advantage with KIR li ...... ntation from unrelated donors.

@nl

type

label

Survival advantage with KIR li ...... ntation from unrelated donors.

@en

Survival advantage with KIR li ...... ntation from unrelated donors.

@nl

prefLabel

Survival advantage with KIR li ...... ntation from unrelated donors.

@en

Survival advantage with KIR li ...... ntation from unrelated donors.

@nl

P1433

Q44399980-7A5F08A8-3BF2-4632-9010-2FCE187BF559

P1476

Q44399980-6DFB6D0A-62C5-4038-9FAD-3B871486C93C

P2093

Q44399980-035EA229-95E0-45ED-A882-8339A267317F

Q44399980-36B597B4-B10A-40CA-9055-D5B1DBA626E0

Q44399980-3806BDE3-BE1B-4CEB-A1C4-9534238B6220

Q44399980-48DE8732-3C91-45ED-B257-62EF5F407129

Q44399980-6438CE5B-68AA-4911-9CAF-C70E776EEC25

Q44399980-6B1FB154-EEC3-4006-A9AF-7C880FE90DDF

Q44399980-840B36DE-CD26-4544-885A-29C186B5A1D7

Q44399980-854E4BE1-D62F-49CE-B9CB-432935DEB1AD

Q44399980-B31C947B-87AC-49C3-9E52-D23ACC775F45

Q44399980-C4D60BD0-E475-4520-A264-C261638E272D

P304

Q44399980-BA52EBAD-C542-4595-93A5-6B23DB28813D

P31

Q44399980-19A04164-629A-4133-AB75-EB7224B312FE

P356

Q44399980-AACEB7B0-6886-4699-BA77-A99F44343AD2

P407

Q44399980-5B42AA8F-60F8-46CD-B4A2-53CA8AEBC1A5

P433

Q44399980-A98F2269-15FB-4A4D-998F-553D0B534FEF

P478

Q44399980-2ADEB8C9-8D58-4D33-8DC5-1E45289DAC5B

P50

Q44399980-8BFB3C2C-F60C-4663-B13B-6B8DAC1AEFFF

P577

Q44399980-F5582C8E-79CB-4098-BEBB-45C2BB4503FF

P5875

Q44399980-5C476826-E149-4818-A5E1-D5D61EE90999

P698

Q44399980-FC49E23F-F744-491C-8B8F-3DD0648E93BD

P356

BLOOD-2003-01-0091

P1433

P1476

Survival advantage with KIR li ...... ntation from unrelated donors.

@en

P2093

Andrea Bacigalupo

http://www.w3.org/2001/XMLSchema#string

Andrea Velardi

http://www.w3.org/2001/XMLSchema#string

Federico Bonetti

http://www.w3.org/2001/XMLSchema#string

Francesco Frassoni

http://www.w3.org/2001/XMLSchema#string

Giovanna Giorgiani

http://www.w3.org/2001/XMLSchema#string

Guido Frumento

http://www.w3.org/2001/XMLSchema#string

Jerzy Holowiecki

http://www.w3.org/2001/XMLSchema#string

Jerzy Wojnar

http://www.w3.org/2001/XMLSchema#string

Miryam Martinetti

http://www.w3.org/2001/XMLSchema#string

Rita Maccario

http://www.w3.org/2001/XMLSchema#string

P304

814-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-01-0091

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Franco Locatelli

P577

2003-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10809566

http://www.w3.org/2001/XMLSchema#string

P698

12689936

http://www.w3.org/2001/XMLSchema#string